| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5599557 | SI PHARMS | Stable hydrated cephalosporin dry powder for oral suspension formulation |
Feb, 2014
(10 years ago) | |
Cedax is owned by Si Pharms.
Cedax contains Ceftibuten Dihydrate.
Cedax has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Cedax are:
- US5599557
Cedax was authorised for market use on 20 December, 1995.
Cedax is available in capsule;oral, for suspension;oral dosage forms.
Cedax can be used as treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis caused by susceptible strains of designated microorganisms in patients 18 years and older..
The generics of Cedax are possible to be released after 04 February, 2014.
Drugs and Companies using CEFTIBUTEN DIHYDRATE ingredient
Market Authorisation Date: 20 December, 1995
Treatment: Treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis caused by susceptible strains of designated microorganisms in patients 18 years and o...
Dosage: CAPSULE;ORAL; FOR SUSPENSION;ORAL
CEDAX family patents
